CEL-SCI presents Head & Neck Cancer data at IDDST

CEL-SCI Corporation announced the Company’s Chief Scientific Officer, Dr. Eyal Talor, delivered a presentation titled “Neoadjuvant Immunotherapy for Head and Neck Cancer: Low Tumor PD-L1 Expression – IT-MATTERS – RCT” at the International Drug Discovery Science & Technology, IDDST, 20th Annual Congress in Budapest, Hungary on Tuesday, June 18, 2024. Dr. Talor presented during the Cancers/Tumors session which he Chaired along with Dr. Elizabeth Tran of Purdue University. The study found: Multikine significantly increases overall survival in patients with low levels of tumor cell PD-L1 expression in contrast to approved checkpoint inhibitors; 73% survival for Multikine vs 45% in the control arm at 5 years; Statistically significant log rank; 5-year risk of death cut in half from 55% to 27%; Hazard ratio = 0.35; Working to commence FDA confirmatory Registration Study for Multikine